Naklofen Duo (Diclofenac Sodium)

Diclofenac sodium blocks the cyclo‑oxygenase enzymes COX‑1 and COX‑2, which are needed to produce prostaglandins. By lowering prostaglandin levels, it diminishes inflammation, pain signaling, and fever, providing relief in affected tissues.

The specific dose and dosing schedule for Naklofen Duo are determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of diclofenac in pregnancy is not well established, and it is generally avoided in the third trimester due to potential fetal risks. Limited data exist for breastfeeding; the decision to use it should be made by a healthcare professional weighing benefits against possible risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Diclofenac sodium offers potent anti‑inflammatory and analgesic effects comparable to ibuprofen or naproxen, but its COX‑2 selectivity may provide slightly stronger pain relief for certain musculoskeletal conditions. Choice of NSAID depends on individual patient risk factors, tolerability, and physician preference.

Naklofen Duo should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, heat, and direct sunlight to maintain product stability throughout its shelf life.

Naklofen Duo is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food may reduce gastrointestinal discomfort. Patients should swallow the tablet whole and not crush or chew it unless directed by a healthcare professional.

Serious risks include gastrointestinal ulceration or bleeding, liver injury, renal impairment, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and increased cardiovascular events like heart attack or stroke. Patients should be monitored for these signs, especially with long‑term or high‑dose therapy.

Naklofen Duo is contraindicated in individuals with known hypersensitivity to diclofenac or other NSAIDs, those with active gastrointestinal ulcer or bleeding, severe heart failure, third‑trimester pregnancy, and patients with significant renal or hepatic impairment unless specifically advised by a physician.